匹多莫德对反复呼吸道感染患儿外周血T淋巴细胞亚群变化的影响及其临床疗效  

Influence of Pidotimod on the Changes of Peripheral Blood T Lymphocyte Subsets for Children with Recurrent Respiratory Tract Infection and its Curative Effects

作　　者：由军[1] 许小红[1] 范慧子[1] 毛春梅[1] 车艺兰 张志程[1] 刘丽晓[1] 

机构地区：[1]哈尔滨医科大学附属第四医院儿科,黑龙江哈尔滨150001

出　　处：《现代生物医学进展》2014年第28期5499-5502,共4页Progress in Modern Biomedicine

摘　　要：目的:研究匹多莫德治疗反复呼吸道感染患儿的临床疗效,并探讨其对患儿外周血T淋巴细胞亚群变化的影响。方法:选择我院收治的160例反复呼吸道感染患儿,根据临床治疗方法将其分成研究组(80例)与对照组(80例),对照组采用抗生素或抗病毒、退热、止咳、平喘与化痰等对症治疗,研究组则在对照组的基础上再加用匹多莫德口服。比较两组患儿外周血T淋巴细胞亚群变化并分析其临床疗效。结果:研究组治疗总有效率显著优于对照组(P<0.05)。研究组治疗后CD3+、CD4+、CD4+/CD8+水平,与治疗前比较明显升高(P<0.05),与对照组同期比较具有明显的差异(P<0.05)。研究组患儿治疗后白细胞计数及中性粒细胞水平,与治疗前比较无明显差异(P>0.05),与对照组同期比较无明显差异(P>0.05);对照组治疗前后白细胞计数及中性粒细胞水平无明显差异(P>0.05)。研究组患儿咳嗽、发热、喘息、肺部啰音消失时间以及抗生素使用时间均明显少于对照组(P<0.01)。研究组与对照组患儿治疗过程中均未发生明显的药物不良反应。结论:匹多莫德治疗反复呼吸道感染患儿疗效确切,能有效改善T淋巴细胞的免疫功能,值得临床推广与应用。Objective： To study the clinical effect of Pi do Maude on the treatment of the recurrent respiratory tract infection for children and to explore its influence on the changes of peripheral blood in T lymphocyte subsets. Methods： 160 cases with repeated respiratory tract who were treated in our hospital were selected and divided into the study group and control group with 80 cases in each one. The patients in the control group were treated by antibiotics, antipyretic, relieving cough and phlegm, the asthma and other symptomatic treatment, while the patients in the study group were treated by the pidotimod besides of the conventional methods. Then the changes of T lymphocyte subsets and clinical efficacy of two groups with peripheral blood were observed and compared. Results： After the treatment, the total efficiency in the study group was significantly better than that of the control group （P〈0.05）. The levels of CD3＋, CD4＋, CD4＋/CD8＋ levels were higher than those of the control group with statistically significant differences （P〈0.05）. There was no statistically significant difference about the white blood cell count and neutrophil levels of patients in the study group after the treatment （P〈0.05）. There was no statistically significant difference between two groups （P〉0.05）. The symptoms of children, which included the cough, fever, wheezing, pulmonary and antibiotic drug use in the study group were significantly less than those of the children in the control group （P〈0.01）. There was no incidence of adverse reaction in the two groups. Conclusion： It is suggested that the Pidomaude could be well promoted in the treatment of recurrent respiratory infection for children which would effectively improve the immune function of T lymphocytes.

关 键 词：反复呼吸道感染 T淋巴细胞 CD4+ CD8+ 匹多莫德 

分 类 号：R56[医药卫生—呼吸系统]